CGM in Type 2 Diabetes: What I Learned From the MOBILE Study

This transcript has been edited for clarity.

Today I'm going to discuss the MOBILE study, which looked at how effective continuous glucose monitoring (CGM) is in people with type 2 diabetes who are treated with basal insulin. I was one of the principal investigators in this study, and we just published the results in JAMA. Let me explain the study and why I think it's important.

This was a randomized controlled trial done at 15 centers in the United States. What's really important to me is that more than half of these centers were treating patients who are underresourced and ethnically diverse; it wasn't the standard higher socioeconomic status population group. This study really tried to get a wider swath of individuals to see if CGM helps.

To get into the trial, patients had to be on one or two daily injections of long- or intermediate-acting basal insulin without prandial insulin, and they could be on any other glucose-lowering medications. The A1c to get into the study started out at > 8% and then was lowered a little bit to > 7.8%. But in the end, the average A1c was around 9.2%.

Another point that was really important is that all of these patients had to be followed by a primary care provider.